Provided by Tiger Trade Technology Pte. Ltd.

Sionna Therapeutics

5.10
-0.1600-3.04%
Post-market: 5.07-0.0300-0.59%19:50 EDT
Volume:1.06M
Turnover:5.40M
Market Cap:229.49M
PE:-2.35
High:5.33
Open:5.26
Low:5.03
Close:5.26
52wk High:54.97
52wk Low:4.01
Shares:45.00M
Float Shares:16.73M
Volume Ratio:0.98
T/O Rate:6.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1683
EPS(LYR):-1.8835
ROE:-32.34%
ROA:-21.54%
PB:0.86
PE(LYR):-2.71

Loading ...

Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Monday Amid Rising Oil Prices

MT Newswires Live
·
Aug 10

Sionna Shares Tumble After Cystic-Fibrosis Treatment Unexpectedly Misses Endpoint

Dow Jones
·
Aug 10

Sionna Scraps Genetic Disorder Drug Program After Trial Setback; Shares Tank

Reuters
·
Aug 10

U.S. Stocks on the MOVE-Apple, Barrick Mining, AbCellera Biologics

Reuters
·
Aug 10

Top Premarket Decliners

MT Newswires Live
·
Aug 10

Sionna Falls After Experimental Drug Misses Mid-Stage Trial Goal

Reuters
·
Aug 10

Sionna Therapeutics Says SION-719 Phase 2a Trial Misses Sweat Chloride Endpoint in Cystic Fibrosis

Reuters
·
Aug 10

Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update

THOMSON REUTERS
·
Aug 10

Sionna Therapeutics, - Evaluating Sion-719 Trial Confounders to Inform Sion-451 Program Next Steps

THOMSON REUTERS
·
Aug 10

Sionna Therapeutics, - Ends Q2 with $268.30 Mln in Cash; Plans Capital Preservation Actions

THOMSON REUTERS
·
Aug 10

Sionna Therapeutics, - Sion-719 Phase 2a Trial Does not Meet Key Endpoint; Program Discontinued as Add-on

THOMSON REUTERS
·
Aug 10

RBC Capital Remains a Sell on Sionna Therapeutics, Inc. (SION)

TIPRANKS
·
Aug 08

Sionna Therapeutics is Maintained at Buy by Guggenheim

Dow Jones
·
Aug 08

Sionna Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Sionna Therapeutics Q2 EPS $(0.66) Misses $(0.65) Estimate

Benzinga Earnings
·
Aug 06

Sionna Net Loss Widens 65.43% to $29.89 Million in Q2 FY26

Reuters
·
Aug 06

Sionna Therapeutics Inc Q2 Basic EPS USD -0.66

THOMSON REUTERS
·
Aug 06

Sionna Therapeutics Inc Q2 Operating Expenses USD 32.47 Million

THOMSON REUTERS
·
Aug 06

Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says

MT Newswires Live
·
Aug 05

Guggenheim Keeps Their Buy Rating on Sionna Therapeutics, Inc. (SION)

TIPRANKS
·
Jul 27